Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

monoclonal antibody BIWA 4

Known as: BIWA 4 (MAb), bivatuzumab 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
This copy has been supplied on the understanding that it is copyright material. Duplication or sale of all or part of any of the… Expand
2013
2013
SUMMARY Hyaluronan (HA)-binding proteins, such as the cell-surface CD44 proteoglycan family and the Receptor for Hyaluronoan… Expand
Highly Cited
2006
Highly Cited
2006
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 4
2006
2006
PURPOSE To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine… Expand
2004
2004
UNLABELLED The aim of this prospective study was to evaluate the safety, pharmacokinetics, immunogenicity, and biodistribution of… Expand
Highly Cited
2003
Highly Cited
2003
Previous studies have shown the potential of murine and chimeric anti-CD44v6 monoclonal antibodies (MAbs) for radioimmunotherapy… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
2003
2003
UNLABELLED From December 1999 until July 2001, a phase I dose escalation study was performed with (186)Re-labeled bivatuzumab, a… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Review
2003
Review
2003
The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3